INFU Stock Analysis: Buy, Sell, or Hold?
INFU - InfuSystem Holdings, Inc.
$9.35
-0.19 (-1.99%)
▼
5d:
-2.6%
30d:
+6.61%
90d:
+4.35%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When INFU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INFU shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: INFU shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$19.96
Based on 14.3% avg growth
INTRINSIC VALUE TODAY
$12.40
24.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INFU is currently trading at $9.35, which is considered fair relative to its 30-day fair value range of $8.65 to $9.85. The stock's valuation (Forward PE: 18.1) is in line with its historical norms (20.0). Remarkably, the market is currently pricing in an annual earnings decline of 3.4% over the next few years. This pessimistic expectation contrasts with the company's recent 123.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, INFU is in a downtrend. Immediate support is located at $8.72, while resistance sits at $10.06.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $14.90 (+59.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INFU is in a downtrend. Immediate support is located at $8.72, while resistance sits at $10.06.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $14.90 (+59.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$8.65 -
$9.85
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 59.4% below Wall St target ($14.90)
Fair Price Analysis
30-Day Fair Range
$8.65 -
$9.85
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$0.84
(9.0%)
Support & Resistance Levels
Support Level
$8.72
Resistance Level
$10.07
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.05
Wall Street Target
$14.90
(+59.4%)
Revenue Growth (YoY)
7.0%
Earnings Growth (YoY)
123.9%
Profit Margin
4.6%
Valuation Discount vs History
-3.4% cheaper
PE vs Historical
18.1 vs 20.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.4%
(market-implied from PE analysis)
1-Year Target
$9.03
(-3%)
2-Year Target
$8.73
(-7%)
3-Year Target
$8.43
(-10%)
3-Yr Target (if PE normalizes)
(PE: 18→20)
$9.34
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 24.5%)
$22.35
(+139%)
Base:
(SPY PE: 18.1, Growth: 24.5%)
$18.05
(+93%)
Bear:
(PE: 15.3, Growth: 24.5%)
$15.34
(+64%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (29x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 29.32 | Current EPS (TTM): $0.31
Bull Case
$16.71
(+74%)
Analyst growth 67.1%, PE expands to 32.3
Base Case
$15.19
(+58%)
Market implied 67.1%, PE stable at 29.3
Bear Case
$6.18
(-36%)
Severe decline -20.0%, PE contracts to 24.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.1 to 20.0
Stabilization Target:
$10.36
(+10.8%)
PE Expansion Potential:
+10.8%
Share & Embed Analysis
Last updated: March 30, 2026 6:37 PM ET
Data refreshes hourly during market hours. Next update: 7:37 PM
Data refreshes hourly during market hours. Next update: 7:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INFU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 51 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 61 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
